Parkman Healthcare Partners’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Parkman Healthcare Partners’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-209,686	Closed	-$4.23M	–	92
2021 Q3	$4.23M	Sell	209,686 -95,000	-31%	-$2.62M	1.07%	31
2021 Q2	$11.4M	Buy	304,686 +1,418	+0.5%	+$43.5K	2.49%	13
2021 Q1	$7.75M	Sell	303,268 -28,245	-9%	-$721K	1.8%	19
2020 Q4	$7.3M	Buy	331,513 +5,650	+2%	+$124K	1.87%	19
2020 Q3	$5.86M	Buy	325,863 +25,058	+8%	+$519K	1.55%	23
2020 Q2	$7.64M	Hold	300,805	–	–	2.15%	13
2020 Q1	$5.53M	Buy	300,805 +60,805	+25%	+$1.18M	2.56%	10
2019 Q4	$5.29M	Buy	+240,000	New	+$4.83M	1.53%	25

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Parkman Healthcare Partners's DRNA Position: Q4 2021 in Review

Parkman Healthcare Partners sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 209,686 shares — an estimated $4.23M sold.

Parkman Healthcare Partners first reported a position in DRNA in Q4 2019 and held it in 8 quarters. The position peaked at $11.4M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Parkman Healthcare Partners reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Parkman Healthcare Partners sold 209,686 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $4.23M.
Parkman Healthcare Partners first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 8 quarters.
Parkman Healthcare Partners's Dicerna Pharmaceuticals, Inc. position peaked at $11.4M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Parkman Healthcare Partners's 13F filing for Q4 2021, filed 11 Feb 2022.